Industry News
Pharmaceutical Industry News
How One Woman With a Very Rare Disease Secured a Clinical Trial
Through sheer determination, Neena Nizar has become the first patient in a clinical trial testing a treatment for her disease — one so rare it affects just 30 people worldwide.
The pharmaceutical industry…
The pharmaceutical industry creates some of the most valuable products in human history: Medicines that can extend, save and better our lives. The product is rarely up for question, but the industry itself can struggle
Politicians and health group…
Politicians and health group leaders in Denmark are calling out Eli Lilly’s obesity awareness campaign in the country.
A U.S. appeals court has revived a…
A U.S. appeals court has revived a lawsuit filed by Celgene shareholders that accuses Bristol Myers Squibb of slow-playing the approval of blood cancer drug Breyanzi to avoid paying out a more than $6 billion
With the European Union formally…
With the European Union formally reversing its marketing authorization for the rare-disease med Tavneos last week, regulators in the bloc are laying out their concerns about the data backing the complement inhibitor in greater detail.
In a historic breakthrough for…
In a historic breakthrough for targeted protein degradation, BMS has secured the first FDA approval for a CELMoD therapy with the clearance of Zenbexus (iberdomide), marking the first multiple myeloma approval driven directly by minimal
As Legend Biotech became…
As Legend Biotech became profitable, the company is navigating Carvykti's next phase of growth. Taiho and Cullinan's EGFR candidate delivered a phase 3 win. WuXi AppTec won a preliminary injunction against the Defense Department's black
With its reserves depleted, a debt…
With its reserves depleted, a debt payment due in four weeks and its cash runway stretching only into next month, the question for Karyopharm Therapeutics is what’s next and how soon can it happen? The
As the massive market for GLP-1…
As the massive market for GLP-1 weight-loss drugs continues to come into its own, patients are just now discovering their preferences, and the appetite for differentiation will likely increase as more drugs are approved in
AstraZeneca’s newly approved…
AstraZeneca’s newly approved blood pressure drug Baxfendy does not clear the bar for effectiveness relative to its price, according to U.S. drug price watchdog ICER.
GLP-1s, AI and telemedicine are…
GLP-1s, AI and telemedicine are changing patient behavior. Learn what it means for diagnosis, engagement and commercialization.
Abbott is again tapping into the…
Abbott is again tapping into the competitive spirit of Big Ten universities to drive blood donations, pitting the schools against each other in pursuit of a $1 million prize amid a national supply crisis.
Roughly a year and a half after…
Roughly a year and a half after the approval of Vykat XR, a group of clinicians with deep ties to the Prader-Willi syndrome (PWS) community is flagging potential concerns about the safety of the rare
Legend Biotech’s interim CEO, Alan…
Legend Biotech's interim CEO, Alan Bash, discusses competition from T-cell engagers and Gilead's new autologous CAR-T as the Carvykti maker posted its first profitable quarter.
Alfasigma will add key drugs like…
Alfasigma will add key drugs like Nordimet through the deal, as well as Nordic Pharma’s women’s health, critical care and ophthalmology portfolios.
Eli Lilly has filed lawsuits…
Eli Lilly has filed lawsuits against six U.S. companies, accusing them of selling illegal versions of its experimental weight-loss drug retatrutide.
Shortly after initiating a…
Shortly after initiating a separate recall tied to mislabeled pain medicine, Fresenius Kabi is yanking a batch of another product in the U.S.
Snapchat is courting pharma…
Snapchat is courting pharma marketers with a new ad format designed to support the disclosure needs of branded prescription drug campaigns.
In the second quarter, nine of the…
In the second quarter, nine of the world's top 25 drugmakers accomplished double-digit revenue increases, led again by Eli Lilly, which charted a 48% sales gain. The revenue boom was even more pronounced when comparing
Despite their divergent…
Despite their divergent second-quarter performance against consensus estimates, BridgeBio and Alnylam are now targeting the same population—first-line ATTR-CM patients—as the silencer-vs-stabilizer debate drags on.